Aldeyra Therapeutics (ALDX) just unveiled an update.
Aldeyra Therapeutics, Inc. has announced the success of its Phase 3 clinical trial for 0.25% reproxalap ophthalmic solution, a potential new treatment for dry eye disease, highlighting the achievement of its primary goal of reducing ocular discomfort. The company will further discuss the results in a conference call, with additional details available on their website. This milestone is significant for investors and those tracking advancements in eye health treatments.
Find detailed analytics on ALDX stock on TipRanks’ Stock Analysis page.
